Three-Dimensional Liver Microtissue for Scalable Hepatocyte Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing liver microtissue are complex, costly, and difficult to scale up, with limited functionality and integration of hepatocytes, leading to insufficient treatment for liver failure.
Innovation Solution
A three-dimensional liver microtissue is developed, comprising at least three different phenotypes of liver cells obtained from induced pluripotent stem cells, with specific metabolic activities and cellular diversity, encapsulated in a closed microcompartment to mimic liver organogenesis, facilitating large-scale production and integration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If hepatocytes are isolated from donors and cultured in vitro, then a large number of patients can be treated, but the hepatocytes undergo dedifferentiation and have limited proliferation capacity, resulting in insufficient mature hepatocytes
Solution Approach 1:
The patent applies preliminary action by differentiating pluripotent stem cells into hepatocytes in a controlled in vitro environment before transplantation. This allows the cells to be prepared and optimized in advance, ensuring they are fully differentiated and functional before being administered to patients, thereby avoiding the dedifferentiation problem that occurs when isolating hepatocytes from donors and culturing them in vitro.
2Quantity of substance
If pluripotent stem cells are used to generate hepatocytes, then an inexhaustible source of hepatocytes is obtained, but the production cost is very high (around 9.7 million dollars for autologous liver grafts)
Solution Approach 1:
The patent applies segmentation by producing small, standardized microtissue units (each containing a limited number of hepatocytes and supporting cells) that can be manufactured efficiently and administered in controlled quantities. This segmented approach allows for scalable production at lower cost compared to generating entire organ grafts from pluripotent stem cells, while still providing sufficient therapeutic effect.
3Reliability
If complex protocols with multiple steps are used to differentiate pluripotent stem cells, then better functional characteristics are obtained, but the total cost increases and control of the finished product decreases
Solution Approach 1:
The patent merges multiple differentiation steps into a single integrated protocol that simultaneously generates hepatocytes and supporting cell types (stellate cells, Kupffer cells, endothelial cells) from pluripotent stem cells. This combined approach maintains the functional quality of the hepatocytes while simplifying the overall process and reducing the number of separate protocol steps required.
4Ease of operation
If single cells are injected to treat liver failure, then the treatment can be administered, but the cells escape into general circulation and integration within the liver is poor
Solution Approach 1:
The patent applies the nested doll principle by encapsulating hepatocytes and supporting cells within a hydrogel microtissue structure. This nested configuration allows the cells to be administered as a unified unit that remains contained within the liver tissue, preventing escape into general circulation while maintaining ease of administration through simple injection. The microtissue structure itself becomes part of the liver architecture, ensuring stable integration.
Data Source
AI summary
The invention relates to a specific liver microtissue, the largest dimension of which is between 500 and 700 μm, which expresses monooxygenase CYP3A4 with an activity of at least 75,000 RLU per million cells and produces at least 18 μg of urea per million cells in 24 hours. The invention also relates to a method for preparing a liver microtissue of this kind and to the uses thereof in the treatment or prevention of liver failure.